GlobeNewswire Inc | Jan 7, 2022 07:05AM EST

January 07, 2022

WILMETTE, Ill., Jan. 07, 2022 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (Nasdaq: MNPR), a clinical-stage biopharmaceutical company focused on developing proprietary therapeutics designed to extend life or improve the quality of life for cancer patients, today announced that Chandler Robinson, MD, Monopars Chief Executive Officer, will present at the H.C. Wainwright BioConnect Conference. The presentation will be available for on-demand viewing starting on Monday, January 10, 2022 at 7:00am ET.

Presentation Details:

Date: Monday, January 10, 2022

Time: 7:00am ET

Location: Virtual

https://hcwevents.com/AboutMonoparTherapeuticsInc.

MonoparTherapeutics is a clinical-stage biopharmaceutical company focused on developing proprietary therapeutics designed to extend life or improve the quality of life for cancer patients.Monopar'spipeline consists of Validivefor the prevention of chemoradiotherapy-induced severe oral mucositis in oropharyngeal cancer patients; camsirubicinfor the treatmentof advanced soft tissue sarcoma; a late-stage preclinical antibody, MNPR-101, for advanced cancers and severe COVID-19; and an early-stage camsirubicin analog, MNPR-202, for various cancers. For more information, visit:www.monopartx.com.

CONTACT:

Monopar Therapeutics Inc.Investor RelationsKim R. TsuchimotoChief Financial Officerkimtsu@monopartx.com

Follow Monopar on social media for updates: Twitter:@MonoparTx LinkedIn:Monopar Therapeutics